HoneyNaps Showcases Innovative Sleep Medicine at World Sleep 2025

HoneyNaps at World Sleep 2025: A New Era in Sleep Medicine

HoneyNaps USA has recently made headlines for its influential participation at the World Sleep Congress 2025, which took place from September 5 to 10 in Singapore. This event, a key gathering for sleep medicine professionals globally, provided HoneyNaps with a fantastic platform to demonstrate its cutting-edge technologies in AI sleep medicine.

At the congress, the company displayed its advanced automatic scoring solutions for polysomnography (PSG), including both the installable version, SOMNUM Pro, and the cloud-based SOMNUM Cloud solution. These FDA-approved tools utilize Artificial Intelligence to streamline the scoring of sleep data, significantly enhancing the efficiency and accuracy of sleep studies.

The Products: SOMNUM Pro and SOMNUM Cloud

SOMNUM Pro is a standalone software suitable for hospital environments, capable of generating detailed PSG reports through AI scoring. This system not only automates data interpretation but also ensures usability by providing a scoring visualization that illustrates how each event is evaluated by the AI.

On the other hand, SOMNUM Cloud offers a more flexible, web-based alternative, eliminating the need for local installations. Users can simply upload EDF files from PSG devices, and the AI performs automatic scoring, producing downloadable reports that comply with HIPAA regulations and boast ISO/IEC 27001 certification. This level of data security has earned the cloud variant high praise in medical communities, particularly concerning the protection of sensitive health information.

Building Connections Across Borders

During the exhibition, HoneyNaps captured the attention of medical professionals from over 35 countries, including major markets in Europe such as the UK, Germany, and France, as well as key Latin American economies like Brazil and Mexico. The company reported a significant increase in visitor engagement compared to previous gatherings, receiving over 260 business inquiries, which resulted in six signed contracts. Additionally, interest in exclusive distributorship agreements flourished, with ongoing discussions to solidify partnerships in various regions.

The enthusiasm shown by potential clients also led to more than 150 trial applications, as many attendees were eager to explore how SOMNUM Cloud could revolutionize their approach to sleep diagnostics.

Future Endeavors

Dr. Taekyoung (Sean) Ha, President of HoneyNaps USA, expressed optimism about the future. He stated, "We will prioritize following up with trial applicants while building local distributor networks and pursuing regulatory approvals in key markets. Our goal is to expand our international footprint with a focus on maintaining our commitment to quality technology and effective service delivery."

This concerted effort aims to enhance HoneyNaps' presence in the global healthcare landscape, where the demand for AI-driven medical solutions continues to surge. By aligning with healthcare professionals through pilot projects and collaborative research, HoneyNaps seeks to develop field applications that address the specific needs of various markets.

As HoneyNaps navigates this promising chapter, it stands poised to play a crucial role in shaping the future of sleep medicine through technology-driven solutions that improve patient outcomes worldwide. For more information, visit HoneyNaps' official website.